Patients with locally advanced colorectal cancer (LACRC) have a high risk of recurrence
and metastasis, although neoadjuvant therapy may provide some benefit. However, patients …

Neoadjuvant chemoradiotherapy (NACRT) or chemotherapy (NACT) followed by radical
resection and then adjuvant therapy is considered the optimal treatment model for locally …

Objective To explore the efficacy and safety of single-agent programmed cell death protein-1
(PD-1) inhibitor in the neoadjuvant treatment of patients with mismatch repair-deficient …

Background Neoadjuvant immunotherapy has shown promising responses in several
cancer types. For colon cancer (CC), NICHE was the first neoadjuvant immunotherapy study …

Background Mismatch repair–deficient (dMMR) tumors can be found in 10 to 15% of patients
with nonmetastatic colon cancer. In these patients, the efficacy of chemotherapy is limited …

Background Colorectal cancer (CRC) is the second most common solid organ cancer.
Traditional treatment is with surgery and chemotherapy. Immunotherapy has recently …

PURPOSE We conducted a systematic review to evaluate the outcome of patients with early-
stage (stages I-III) mismatch repair deficient (dMMR) colorectal cancer (CRC) receiving …

Importance Colorectal cancers (CRCs) with deficient DNA mismatch repair (dMMR) account
for 15% of all CRCs. Deficient MMR is a predictive biomarker associated with …

Colorectal cancer (CRC) remains a leading cause of cancer-related deaths in the United
States. Although immunotherapy has dramatically changed the landscape of treatment for …

Background Patients with colorectal carcinoma and high-grade microsatellite instability (MSI-
H) or deficiency in mismatch repair (dMMR) exceptionally respond to immune checkpoint …